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Abstract
In order to model the effect of PTPN22  on rheumatoid arthritis (RA), we determined the
combination of single-nucleotide-polymorphisms (SNPs) showing the strongest association with
RA. Three SNPs (rs2476601-rs12730735-rs11102685) were selected for which we estimated the
genotypic relative risks (GRRs) of the corresponding genotypes. On the basis of these GRRs we
defined four at-risk genotypic classes. Relative to the class of reference risk, individuals had a risk
approximately multiplied by two, three, or four. This classification was confirmed by the excess of
identity-by-descent (IBD) sharing (IBD = 2) for the sibs of an index in the high-risk class and by
excess of non-IBD sharing (IBD = 0) when the index belonged to the low-risk class. The observed
data could not be explained by the role of a single variant but were compatible either with a joint
effect of the three typed SNPs of PTPN22 on RA or with the role of two untyped variants.
Background
The single-nucleotide polymorphism (SNP) R620W, also
denoted rs2476601, is located within the hematopoietic-
specific protein tyrosine phosphatase gene, PTPN22. This
SNP (C/T) codes for an amino-acid change and the fre-
quency of its minor allele T has been recently and repeat-
edly shown to be increased in patients with rheumatoid
arthritis (RA) [1]. The allele T confers 1.7- to 1.9-fold
increased risk to heterozygote and higher risks to homozy-
gote carriers [2] compared to the non-carrier individuals.
This variant is also well known to be associated with sev-
eral other autoimmune diseases [3], such as systemic
lupus erythematosus and type 1 diabetes. Recently, Carl-
ton et al. [2] studied the PTPN22 genetic variations in the
North American Rheumatoid Arthritis Consortium
(NARAC) data. Using the information on several SNPs
typed in PTPN22, they compared the haplotype distribu-
tions in NARAC patients and controls. They demonstrated
that SNP R620W does not fully explain the association
between PTPN22 and RA and suggested the effect of at
least one additional variant in the PTPN22 gene.
We propose here to reanalyze the NARAC data using both
association and linkage information for modeling the role
of PTPN22 in RA.
Methods
Data
We selected from the NARAC data the 511 families with
affected sib pairs typed for 14 SNPs of PTPN22, and 1404
unrelated controls also typed for all these SNPs. For each
affected sib pair we considered the proband as an index
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RA patient. The R620W SNP is one of the 14 SNPs in
PTPN22. It is located at the ninth position, so it will be
subsequently denoted as SNP 9. A preliminary study of
linkage disequilibrium (LD) among the 14 SNPs was
examined in the 1404 controls. The LD analysis lead us to
exclude 3 SNPs (SNP 2, SNP 12, SNP 13), which are in
complete LD with one (or more) other SNP(s).
Selection of associated SNPs
The combination test [4] was used on the 11 remaining
SNPs to select the subset of SNPs showing a significant
difference in the genotypic distribution between RA index
patients and controls. Its principle consists in testing all
possible combinations of SNPs within a gene. Here, there
are (211-1) possible combinations. Such a systematic test-
ing of all SNPs and all SNP combinations raises the prob-
lem of multiple and non-independent tests. This problem
is generally solved by the implementation of a permuta-
tion procedure that allows estimation of corrected p-val-
ues. Here, associated combinations are very significant
and the number of permutations necessary to discrimi-
nate them would be extremely high and almost unreach-
able. Nevertheless, the chi-square values of the genotypic
association test are so high that even the conservative Bon-
ferroni correction can be used. We selected the most asso-
ciated and parsimonious subset of SNPs by nested chi-
square tests (NCST) in a forward procedure. The NCST
compares the strength of association between nested sig-
nificant subsets.
Genotypic relative-risk estimation
For the selected subset of SNPs, we used the marker asso-
ciation segregation chi-square (MASC) method [5] to
compute the genotypic relative risk (GRR) of each geno-
type. The genotype distributions of index and controls
was conditional on the fact that the index has an affected
sib.
Stratified sib pair IBD estimation
Conditional on each marker genotype of the index cases,
the number of parental alleles identical by descent (IBD)
shared by the index case and one affected sib were esti-
mated on PTPN22 with the MERLIN software [6]. MER-
LIN is able to take into account LD between SNPs during
the IBD computation. So the estimated IBD distributions
are computed on the overall set of SNPs even if they are in
LD. The fit of a model to the IBD distributions stratified
on index marker genotypes [7] may then be tested by the
MASC method.
Modeling PTPN22 effect
We applied the MASC method [5] to find the most parsi-
monious model explaining the overall observations, i.e.,
the genotype and the stratified sib-pair IBD distributions.
To do this, MASC requires the haplotype frequencies in
the general population, which were estimated on the
unrelated controls by the MERLIN software.
The MASC method computes the expected genotype
marker distribution and the expected sib-pair IBD distri-
butions stratified on marker genotypes for a given genetic
model. Here, the computation of the genotypic distribu-
tion is conditioned on the fact that index cases have an
affected sib. The global expected likelihood of the genetic
model given the observed data is then computed as the
product of the likelihoods of each expected distribution,
and is maximized on the model parameters. The fit of the
model to the observed data is tested by a likelihood ratio
test (LRT) between global expected likelihood and the
likelihood of the saturated model.
Results
Selection of associated SNPs
Many subsets of SNPs show significant associations. Table
1 presents a selection of the most associated combina-
tions of one, two, and three SNPs. When considering only
the effect of a single SNP, the only significant associated
one after correction for multiple testing is SNP 9. The
combination of SNPs 9–10 is the one which, among the
combination of two SNPs, best improves the association
shown by the SNP 9 alone (p = 0.017). The subset SNPs 9-
10-11 (rs2476601-rs12730735-rs11102685) is the only
one that improves significantly the association shown by
the SNPs 9–10 (p = 0.038). Adding another SNP to this
subset does not significantly improve the association.
Consequently, all the subsequent analyses have been
done considering SNPs 9-10-11 and their ten correspond-
ing genotypes.
GRR estimation
Table 2 displays the genotypes and the corresponding
GRRs for SNP 9 taken alone (columns 1 and 2) and for the
set of the three SNPs 9-10-11 (columns 3 and 4). The
GRRs vary from 1 to 2.7 when considering only SNP 9,
whereas the variation ranges from 1 to 4.7 when the infor-
mation on the three SNPs is taken into account. Interest-
ingly, the CC genotype of the SNP 9 can be subdivided in
several genotypes when taking into account the genotypes
for SNPs 10 and 11 (rows 1 to 6) with GRRs ranging from
1 (CC-GG-AA) to 3.6 (CC-AA-GG). This observation dem-
onstrates the importance of using the additional informa-
tion on SNPs 10–11.
Sib pair IBD estimation
The proportion of RA sibs sharing 0, 1, or 2 parental alle-
les for PTPN22 is 0.26 (181 pairs), 0.51 (362 pairs), and
0.23 (167 pairs), respectively, and does not differ from the
IBD distribution 0.25; 0.5; 0.25 expected under no link-
age. However, if our GRRs correctly reflect the differential
risk of RA, we expect to see differences in the IBD vectorsBMC Proceedings 2007, 1(Suppl 1):S37 http://www.biomedcentral.com/1753-6561/1/S1/S37
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stratified on the genotypes of the subset of SNPs 9-10-11
[7]. To avoid cells with small numbers of individuals we
pooled sib pairs with the index genotypes (SNP 9-10-11)
that have similar risk. We thus defined four arbitrary at
risk genotypic classes: the low risk class (L; GRR = 1; 19
pairs), the intermediate risk class 1 (I1; 1 < GRR ≤ 2; 295
pairs), the intermediate risk class 2 (I2; 2 < GRR ≤ 3; 157
pairs), and the high risk class (H; GRR > 3; 34 pairs).
Table 3 shows that the proportion of IBD = 0 decreases
from 0.47 to 0.09 according to the fact that the index
belongs to class L or class H and conversely, the propor-
tion of IBD = 2 increases from 0.11 to 0.26. These strati-
fied IBD distributions are consistent with the risk
genotypic classes. In contrast, the IBD sharing distribu-
tions stratified only on SNP 9 genotypes are not consistent
with the GRR estimates on this SNP (Table 4).
Modeling PTPN22 effect
We apply the MASC method in using the genotype distri-
bution only on the SNP 9 and the IBD stratified on the
SNP 9 genotypes. In that case, the single and causal effect
of the SNP 9 is not rejected (p = 0.29). Then, we model the
effect of PTPN22 using the four genotypic groups of risk
defined on the genotypes of the combination of the SNPs
9-10-11 and the IBD information stratified on them. In
this case, we reject the direct effect of SNP 9 (p = 0.005).
We also reject the effect of a single untyped SNP (p =
0.04). However, we do not reject the interactive effect of
the 3 SNPs (p  = 0.53) or the interactive effect of two
untyped SNPs.
Discussion
The involvement of PTPN22 and HLA in RA susceptibility
is no longer disputed. However, as shown by Carlton et al.
and confirmed in this study, the role of PTPN22 cannot be
explained only by the R620W SNP.
A correct modeling of PTPN22 is important and shows
that the genotypic risk varies much more (1 to 4.7) than
reported in the literature (1 to 2.7) [4]. In this study we
proposed, for the first time, a model for the effect of
PTPN22, taking into account both association and linkage
information.
Another method, called LAMP [8] was recently proposed
for joint modeling of linkage and association [8]. The
linkage information used by the LAMP method is the glo-
bal IBD sharing of affected sib pairs. However, it is very
important to note that the power of model discrimination
strongly depends on the association and linkage informa-
tion that is used. As shown here, the information on SNP
9 alone and on the global IBD is very poor as compared
with that of the three SNPs 9-10-11 and to the stratified
IBD distributions on the four at-risk genotype groups.
In conclusion, we applied a four-step strategy to model
the effect of a candidate gene covered by several SNPs: 1)
to select the most associated set of SNPs; 2) to group the
corresponding genotypes according their GRRs; 3) to
stratify IBD sharing information on the at-risk genotype
groups; 4) to model the effect of the candidate gene while
Table 3: IBD distribution stratified on the index classes for the 
four risk classes number of individuals (in parentheses)
Risk class IBD = 0 IBD = 1 IBD = 2
L 0.47 (9) 0.42 (8) 0.11 (2)
I1 0.29 (85) 0.49 (146) 0.22 (64)
I2 0.26 (41) 0.50 (78) 0.24 (38)
H 0.09 (3) 0.65 (22) 0.26 (9)
Table 2: GRR estimates
SNP 9 GRR SNP 9-10-11 GRR
CC 1 CC-AA-AA 1.60
CC-AA-AG 1.76
CC-AA-GG 3.60
CC-AG-AA 1.73
CC-*G-AGa 2.35
CC-GG-AA 1
CT 1.66 CT-AA-AA 2.88
CT-AA-AG 3.11
CT-AG-AA 2.61
TT 2.7 TT-A*-AAa 4.68
a *, either the A or the G alleles of SNP 10.
Table 1: Most associated subsets of one, two and three SNPs
Subset χ2 df χ2 value Corrected p-value Compared subsets NCST df NCST value NCST p-value
9 2 47.6 9.5×10-8 -- - -
4_9 4 54.0 11.0×10-8 4_9 vs. 9 2 6.4 0.041
9_10 7 61.3 17.2×10-8 9_10 vs. 9 5 13.7 0.017
9_11 5 57.3 9.2×10-8 9_11 vs. 9 3 9.7 0.021
9_10_11 12 73.0 17.8×10-8 9_10_11 vs. 9_10 5 11.7 0.038Publish with BioMed Central    and   every 
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taking into account both linkage and association informa-
tion.
This strategy allowed better modeling of the effect of
PTPN22 in RA susceptibility. Recently, du Montcel et al.
[9] refined the modeling of HLA in RA susceptibility. A
next step will be to use simultaneously the PTPN22 and
HLA information to evaluate their joint effects while tak-
ing into account important covariables such as age and
gender.
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Table 4: IBD distribution for the three genotypes of the SNP 9 
number of individuals (in parentheses)
Genotype of index IBD = 0 IBD = 1 IBD = 2
CC 0.27 (96) 0.49 (177) 0.24 (85)
CT 0.25 (35) 0.53 (75) 0.22 (31)
TT 0.14 (2) 0.65 (10) 0.21 (3)
aIBD distributions stratified on the index genotypes are given in 
proportions and in effectives.